Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

News Spotlights Stocks

Credit Suisse downgrades Pfizer stock, sees 15% downside risk

post-img

Credit Suisse analysts downgraded shares of Pfizer (NYSE:PFE) from Outperform to Neutral with a price target of $40 per share, down from the prior $47.

The new price target suggests a downside risk of roughly 15%. Shares are down 0.7% in pre-open Thursday.

“As Pfizer enters a period of uncertainty and limited pipeline catalysts, we see greater opportunity for growth among other US Major peers,” said the analysts.

They highlighted several concerns, including decreased confidence in the mid-to-long-term guidance for COVID vaccines and “a show-me launch story” for the RSV vaccine.

The downgrade move comes despite an “attractive valuation.”

“However, the rerating from pipeline catalysts and BD has not emerged this year as we had thought. We see it tough to turn sentiment around given the uncertainty as we enter commercial COVID pricing, less BD, and a lack of meaningful catalysts on the horizon. We need to see execution in order to be comfortable with management’s ambitious expectations (pipeline peak sales/COVID/Flu),” the analysts concluded.

Related Post